Cargando…
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer
The 21-gene recurrence score (RS) is prognostic for distant recurrence (DR) and predictive for chemotherapy benefit in early breast cancer, whereas clinical-pathological factors are only prognostic. Integration of genomic and clinical features offers the potential to guide adjuvant chemotherapy use...
Autores principales: | Sparano, Joseph A., Crager, Michael R., Tang, Gong, Gray, Robert J., Stemmer, Salomon M., Shak, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078482/ https://www.ncbi.nlm.nih.gov/pubmed/33306425 http://dx.doi.org/10.1200/JCO.20.03007 |
Ejemplares similares
-
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
por: Geyer, Charles E., et al.
Publicado: (2018) -
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018) -
Transient myeloproliferative disorder as the presenting feature for mosaic trisomy 21
por: Baca, Nicole, et al.
Publicado: (2021) -
The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database
por: Choi, In Sil, et al.
Publicado: (2020) -
Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
por: Makower, Della, et al.
Publicado: (2021)